TY - JOUR
T1 - Biosimilar filgrastim uptake and costs among commercially insured, medicare advantage
AU - Karaca-Mandic, Pinar
AU - Chang, Jessica
AU - Go, Ronald
AU - Schondelmeyer, Stephen
AU - Weisdorf, Daniel
AU - Jeffery, Molly Moore
N1 - Funding Information:
The research reported in this article was funded by the American Cancer Society (ACS) (Grant No. RSGI-17-154-01-CPHPS). Pinar Karaca-Mandic was the principal investigator, Jessica Chang was a graduate student research assistant, and the other authors were coinvestigators on the grant. Karaca- Mandic reports receiving consulting fees unrelated to this article in the past thirty-six months from Tactile Medical and Precision Health Economics. Chang is also an off-campus research assistant at OptumLabs, conducting research studies. Molly Jeffery is supported by the ACS grant that funded this study. She is also funded by the National Heart, Lung, and Blood Institute (Grant No. R21HL 140287) for a project on initiation and discontinuation of biologic therapies for asthma. She has additional unrelated funding from the National Center for Advancing Translational Sciences (Grant No. U01 TR 02743) and the National Institute on Drug Abuse (Grant No. UG3DA047003).
Publisher Copyright:
© 2019 Project HOPE— The People-to-People Health Foundation, Inc.
PY - 2019/11
Y1 - 2019/11
N2 - In 2015 the Food and Drug Administration approved filgrastim-sndz (Zarxio), the first US biosimilar. Following rapid uptake, by March 2018 filgrastim-sndz accounted for 47 percent of filgrastim administrations among commercially insured and 42 percent among Medicare Advantage beneficiaries. The initial cost difference between the originator and biosimilar was 31 percent in the former population but negligible in the latter.
AB - In 2015 the Food and Drug Administration approved filgrastim-sndz (Zarxio), the first US biosimilar. Following rapid uptake, by March 2018 filgrastim-sndz accounted for 47 percent of filgrastim administrations among commercially insured and 42 percent among Medicare Advantage beneficiaries. The initial cost difference between the originator and biosimilar was 31 percent in the former population but negligible in the latter.
UR - http://www.scopus.com/inward/record.url?scp=85074548046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074548046&partnerID=8YFLogxK
U2 - 10.1377/hlthaff.2019.00253
DO - 10.1377/hlthaff.2019.00253
M3 - Article
C2 - 31682491
AN - SCOPUS:85074548046
VL - 38
SP - 1887
EP - 1892
JO - Health Affairs
JF - Health Affairs
SN - 0278-2715
IS - 11
ER -